These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 27593971)

  • 1. Frontal glioblastoma multiforme may be biologically distinct from non-frontal and multilobar tumors.
    Paldor I; Pearce FC; Drummond KJ; Kaye AH
    J Clin Neurosci; 2016 Dec; 34():128-132. PubMed ID: 27593971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. O
    Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
    Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH1 mutation may not be prognostically favorable in glioblastoma when controlled for tumor location: A case-control study.
    Paldor I; Drummond KJ; Kaye AH
    J Clin Neurosci; 2016 Dec; 34():117-120. PubMed ID: 27522495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
    Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
    Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study of glioblastoma multiforme in elderly patients: treatments, O-6-methylguanine-DNA methyltransferase (MGMT) methylation status and survival.
    Abhinav K; Aquilina K; Gbejuade H; La M; Hopkins K; Iyer V
    Clin Neurol Neurosurg; 2013 Aug; 115(8):1375-8. PubMed ID: 23333005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.
    Tabei Y; Kobayashi K; Saito K; Shimizu S; Suzuki K; Sasaki N; Shiokawa Y; Nagane M
    Jpn J Clin Oncol; 2021 Jan; 51(1):45-53. PubMed ID: 32888020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Relevance of Tumor Purity and Interaction with MGMT Methylation in Glioblastoma.
    Schulze Heuling E; Knab F; Radke J; Eskilsson E; Martinez-Ledesma E; Koch A; Czabanka M; Dieterich C; Verhaak RG; Harms C; Euskirchen P
    Mol Cancer Res; 2017 May; 15(5):532-540. PubMed ID: 28148826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia.
    Polivka J; Polivka J; Rohan V; Pesta M; Repik T; Pitule P; Topolcan O
    Biomed Res Int; 2014; 2014():735659. PubMed ID: 24511544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
    Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
    Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Perampanel in the treatment of a patient with glioblastoma multiforme without IDH1 mutation and without MGMT promotor methylation].
    Rösche J; Piek J; Hildebrandt G; Grossmann A; Kirschstein T; Benecke R
    Fortschr Neurol Psychiatr; 2015 May; 83(5):286-9. PubMed ID: 26018396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is Ki-67 index overexpression in IDH wild type glioblastoma a predictor of shorter Progression Free survival? A clinical and Molecular analytic investigation.
    Armocida D; Frati A; Salvati M; Santoro A; Pesce A
    Clin Neurol Neurosurg; 2020 Nov; 198():106126. PubMed ID: 32861131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glioblastoma with oligodendroglioma component (GBM-O): molecular genetic and clinical characteristics.
    Appin CL; Gao J; Chisolm C; Torian M; Alexis D; Vincentelli C; Schniederjan MJ; Hadjipanayis C; Olson JJ; Hunter S; Hao C; Brat DJ
    Brain Pathol; 2013 Jul; 23(4):454-61. PubMed ID: 23289977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor location and patient age predict biological signatures of high-grade gliomas.
    Altieri R; Zenga F; Ducati A; Melcarne A; Cofano F; Mammi M; Di Perna G; Savastano R; Garbossa D
    Neurosurg Rev; 2018 Apr; 41(2):599-604. PubMed ID: 28856492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipidized glioblastoma: pathological and molecular characteristics.
    Singh AD; Iftinca M; Easaw JC
    Neuropathology; 2013 Feb; 33(1):87-92. PubMed ID: 22640269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme.
    De Carlo E; Gerratana L; De Maglio G; Buoro V; Cortiula F; Gurrieri L; Isola M; Fasola G; Puglisi F; Pizzolitto S; Rizzato S
    J Neurooncol; 2018 Dec; 140(3):559-568. PubMed ID: 30132165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis.
    Dahlrot RH; Dowsett J; Fosmark S; Malmström A; Henriksson R; Boldt H; de Stricker K; Sørensen MD; Poulsen HS; Lysiak M; Söderkvist P; Rosell J; Hansen S; Kristensen BW
    Neuropathol Appl Neurobiol; 2018 Feb; 44(2):172-184. PubMed ID: 28574607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
    Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
    Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
    Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
    J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.